These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38373149)

  • 1. Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer.
    Nasrollahi E; Davar D
    Cancer Immunol Res; 2024 Apr; 12(4):383-384. PubMed ID: 38373149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
    De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
    Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
    de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
    Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
    Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the RANK/RANKL pathway in breast cancer.
    Kiesel L; Kohl A
    Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
    Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
    Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis.
    Li B; Wang P; Jiao J; Wei H; Xu W; Zhou P
    Front Immunol; 2022; 13():824117. PubMed ID: 35386705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
    Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
    Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab for the treatment of bone metastases in advanced breast cancer.
    Casas A; Llombart A; Martín M
    Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab: the era of targeted therapies in bone metastatic diseases.
    Santini D; Fratto ME; Vincenzi B; Napoli N; Galluzzo S; Tantardini M; Abbruzzese A; Caraglia M; Tonini G
    Curr Cancer Drug Targets; 2009 Nov; 9(7):834-42. PubMed ID: 20025571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.
    Sköld C; Kultima K; Freyhult E; Larsson A; Gordh T; Hailer NP; Mallmin H
    Osteoporos Int; 2022 Sep; 33(9):1-8. PubMed ID: 35608639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
    Chang H; Marquez J; Chen BK; Kim DM; Cheng ML; Liu EV; Yang H; Zhang L; Sinha M; Cheung A; Kwek SS; Chow ED; Bridge M; Aggarwal RR; Friedlander TW; Small EJ; Anderson M; Fong L
    Cancer Immunol Res; 2024 Apr; 12(4):453-461. PubMed ID: 38276989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
    van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
    Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.